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Recent studies of perimenopausal women suggest that follicle-stimulating hormone (FSH) levelsmay be associated
with atherosclerosis, independent of estradiol. Whether FSH is related to atherosclerosis in older postmenopausal
women, who have completed the menopausal transition, remains unknown. We assessed the relationship of serum
FSH and estradiol levels with carotid artery intima-media thickness (IMT) among 587 postmenopausal participants in
the Kuopio Ischemic Heart Disease Risk Factor Study (Kuopio, Finland). Participants were aged 53–73 years and not
using hormone therapy at baseline (1998–2001). Mean IMT was measured via high-resolution ultrasonography. We
observed a significant inverse association between FSH levels and IMT.Mean IMTs amongwomen in quartiles 1–4 of
FSH were 0.94mm, 0.91mm, 0.87mm, and 0.85mm, respectively (P-trend < 0.001). After adjustment for age, estra-
diol, testosterone, body mass index (weight (kg)/height (m)2), lipids, and other factors, FSH levels remained signifi-
cantly associated with IMT (regression coefficients for quartiles 2–4 vs. quartile 1 were −0.038, −0.045, and −0.062,
respectively; P-trend = 0.01). Findings were strongest in women aged 64–73 years (P-trend = 0.006) and did not vary
by body mass index. In contrast, estradiol levels were not related to IMT. In summary, high postmenopausal FSH levels
were associated with a lower atherosclerotic burden, independent of estradiol, adiposity, and other factors. Our findings
warrant replication and the further exploration of potential underlyingmechanisms.
atherosclerosis; carotid intima-media thickness; estradiol; follicle-stimulating hormone; postmenopausal women
Abbreviations: BMI, body mass index; CCA, common carotid artery; CVD, cardiovascular disease; FSH, follicle-stimulating
hormone; IMT, intima-media thickness; KIHD, Kuopio Ischemic Heart Disease Risk Factor.
The role of sex steroids in cardiovascular health in women
after menopause remains controversial. While higher levels
of estradiol across the menopausal transition have been associ-
ated with a lower atherosclerotic burden (1–3), recent studies
suggest that follicle-stimulating hormone (FSH) levels may be
positively associated with atherosclerosis, independent of
estradiol (1). However, these studies have almost exclusively
considered FSH levels in women still undergoing the meno-
pausal transition, when sex steroid levels are highly dynamic
(1–6). The relationship of serum FSH and residual circulat-
ing estradiol levels to cardiovascular health in late postmen-
opausal women, after the most pronounced fluctuations in
ovarian estrogen production have stabilized, remains virtu-
ally unknown.
We assessed the relationship of serum FSH and estradiol
levels with common carotid artery (CCA) intima-media thick-
ness (IMT), a measure of atherosclerosis, among women aged
53–73 years participating in the Kuopio Ischemic Heart Disease




The KIHD Study is an ongoing prospective population-based
cohort study of risk factors for cardiovascular disease (CVD)
and metabolic conditions in men and women living in eastern
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Finland. While male participants were enrolled in 1984–1989,
female participants were first enrolled between March 1998 and
February 2001, corresponding to the 11-year follow-up visit for
male participants.Women eligible for enrollment were a random
sample of 1,173 postmenopausal women living in the city of
Kuopio and surrounding rural communities. Women from
4 specific age groups were selected: 53–56 years, 59–62
years, 64–68 years, and 71–73 years. Of eligible women,
920 completed baseline clinical assessments and joined
the cohort (78.4%). Among nonparticipants, 168 refused par-
ticipation, 51 could not be contacted, and 34 were excluded for
other reasons. The study protocol was approved by the Research
Ethics Committee of the University of Kuopio. Informed con-
sent was obtained from all participants.
Clinical measurements
At a clinical interview, participants completed a comprehen-
sive clinical examination, during which CCA IMT was mea-
sured by high-resolution B-mode ultrasonography (Biosound
Phase 2; Biosound Inc., Indianapolis, Indiana), as described pre-
viously (7). Briefly, measurements were made at the distal end
of the right and left CCAs, proximal to the carotid bulb, and vid-
eotaped for computerized analysis with PROSOUND software
(University of Southern California, Los Angeles, California) (8).
Measurements of the intima-lumen and media-adventitia inter-
faces were made at approximately 100 points along a 1.0- to
1.5-cm section of the right and left CCAs by edge-detection
algorithm. For each participant, approximately 100 measure-
ments from the right CCA and 100 from the left CCA were
averaged to calculate mean IMT. Interrater reliability of IMT
measurements among male KIHD participants was assessed
previously, with correlation coefficients across raters ranging
from 0.90 to 0.99 (9).
Resting systolic and diastolic blood pressures were calculated
as the average of 6measurements: 3 taken while the participant
lay supine after 5 minutes’ rest; 1 taken while the participant
was standing; and 2 taken while the participant was sitting, with
5 minutes between measurements. Height and weight were
directly measured and used to calculate body mass index
(BMI; weight (kg)/height (m)2). Waist and hip circumferences
were measured with a standard measuring tape and used to
calculate waist:hip ratio.
Blood collection and biochemical measurements
At the clinical interview, fasting blood sampleswere collected
between 8:00 AM and 10:00 AM, after participants had abstained
from eating or smoking cigarettes for 12 hours and consuming
alcohol for 3 days. Serum was separated from other blood com-
ponents within 60 minutes and stored at −20°C or −80°C until
assay.
Samples were assayed for FSH between June 2001 and
February 2002. Serum FSH concentration was determined
with a sandwich technique applying an immunoradiometric
assay manufactured by Diagnostic Products Corporation
(Coat-A-Count FSH IRMA; Diagnostic Products Corporation,
Los Angeles, California). For quality control, triplicates of low,
medium, and high Lyphochek controls (Bio-Rad Laboratories,
Anaheim, California) were included in each run. Coefficients of
variation were 5% for each set of controls. Serum 17β-estradiol
was assayed between 1999 and 2001 with a radioimmunoassay
manufactured by DiaSorin (DiaSorin S.p.A., Stillwater, Minne-
sota). Four different types of controls were included in each run:
Lyphochek low and medium controls, an in-house serum pool,
and a control provided by the kit manufacturer. Concentrations
of 17β-estradiol were in the physiological range for the in-house
pool and higher for other types of controls. Coefficients of varia-
tion ranged from 7.6% (in-house pool) to 12.0% (manufacturer’s
control). Serum testosterone (17β-hydroxy-4-androsten-3-one)
concentration was determined with the Spectria Testosterone
125I radioimmunoassay kit (Orion Diagnostica, Espoo, Finland).
Three different controls were included in each assay: Lyphochek
low, medium, and high. Coefficients of variation ranged from
7.9% (high control) to 12.2% (low control). 125I-labeled mea-
surements for FSH, estradiol, and testosterone were carried out
by means of the Wallac 1261 MultiGamma gamma counter
(PerkinElmer Wallac Oy, Turku, Finland) using RiaCalc LM
software (PerkinElmer Wallac Oy). Sex hormone-binding
globulin was evaluated using the 1235 AutoDELFIA auto-
matic immunoassay system (PerkinElmer Wallac Oy) based
on a time-resolved fluoroimmunoassay (10).
Samples from all participants were assayed for levels of total,
high-density lipoprotein, and low-density lipoprotein choles-
terol, triglycerides, glucose, insulin, and C-reactive protein using
laboratory methods described in detail previously. Briefly, the
cholesterol contents of lipoprotein fractions and serum triglyc-
erides were measured enzymatically; high-density lipoprotein
fractions were separated from serum by combined ultracentrifu-
gation and precipitation (11, 12). Glucose was measured using
a glucose dehydrogenase method after precipitation of proteins
by trichloroacetic acid (13). Serum insulin was determine with
a Novo BioLabs radioimmunoassay kit (NovoNordisk, Bags-
vaerd, Denmark). C-reactive protein was measured via high-
sensitivity immunometric assay (Immulite High Sensitivity
CRP Assay; Diagnostic Products Corporation).
Questionnaire assessments
Participants reported data on demographic, behavioral, repro-
ductive, and health-related factors on questionnaires, which were
then reviewed by a trained interviewer for completeness and
clarity. Reproductive factors included age at menarche, his-
tory and duration of oral contraceptive use, number of full-term
pregnancies, age at last menses, and history of hysterectomy and
oophorectomy; use of hormone therapy (ever use, current use,
and total duration) was also assessed. Postmenopausal status
and age at menopause were defined by the absence of menses
for at least 12 months, or at the time of oophorectomy for
women who reported having undergone surgery prior to meno-
pause. Physical activity was assessed with the KIHD 12-Month
Leisure Time Physical Activity History questionnaire (14) and
was used to estimate amount of physical activity (metabolic
equivalent of task hours) per day.
Study physicians conducted interviews to record each partici-
pant’s history of CVD and metabolic disorders and her use of
medications for hypertension, diabetes, heart disease, angina
pectoralis, and high cholesterol. Each participant also completed
4 days of diet records and a detailed alcohol use questionnaire,
whichwere used to estimate total energy and alcohol intake (15).
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Statistical analysis
The present analysis was limited to women not using hor-
mone therapy (n = 588). Onewomanwasmissing an IMTmea-
surement and was therefore excluded, which gave us a final
analytical sample size of 587.We divided participants into quar-
tiles of FSH and estradiol and compared baseline characteristics
across quartiles, using analysis of variance for continuous vari-
ables and χ2 tests for categorical factors.
We then used multivariable linear regression to assess the re-
lationships of FSH and estradiol levels with mean IMT. IMT
values were transformed (negative reciprocal transformation) to
improve normality and meet model assumptions. To evaluate
the potential for confounding, we then built a series of models.
Inmodel 1, we adjusted for age and year of examination;models
for estradiol also adjusted for FSH, andmodels for FSH adjusted
for estradiol. Model 2 included model 1 variables plus measures
of adiposity (BMI and waist:hip ratio). Model 3 included model
2 variables plus behavioral and biochemical factors associated
with IMT, FSH, and/or estradiol levels in this population. These
included physical activity, past use of hormone therapy, duration
of use of hormone therapy, smoking status (current, past, or
never smoker), pack-years of cigarette smoking, alcohol intake
(g/week), number of full-term pregnancies, age at menopause,
systolic and diastolic blood pressure, and levels of testosterone,
sex hormone-binding globulin, total cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol, tri-
glycerides, glucose, insulin, and C-reactive protein. Model 4
includedmodel 3 variables and further adjusted for CVD history
and medication use, including history of hypertension, type 2
diabetes, symptomatic heart disease, or stroke and current use of
medication for hypertension, coronary heart disease, high cho-
lesterol, or diabetes. Linear trends across quartiles of FSH and
estradiol were assessed by modeling the median values of all
quartiles as a continuous variable.
We conducted stratified analyses to evaluate whether associa-
tions between hormones and IMT in model 4 varied by age and
BMI. Effect modification was assessed with multiplicative inter-
action terms, and a Wald test result of P < 0.05 was considered
significant. In sensitivity analyses, we excluded women reporting
any history of CVD and those reporting use of CVD medica-
tion.We also repeated our main analysis evaluating associations
between hormones and maximum IMT values. Statistical analy-
seswere completedwith SPSS (SPSS Inc., Chicago, Illinois), ver-
sion 21.0 forWindows (IBMCorporation, Armonk, NewYork).
RESULTS
Characteristics of study participants by quartile of serum FSH
concentration are presented in Table 1. In univariate analyses,
women with the highest FSH levels were younger and had a
lower BMI, waist:hip ratio, and estradiol level than women
with lower FSH levels. Mean levels of systolic blood pressure,
triglycerides, fasting insulin, and glucosewere lower in women
with higher FSH levels, while levels of total and high-density
lipoprotein cholesterol were significantly higher. Women with
higher FSH levels were less likely to report medication use for
hypertension, symptomatic heart disease, type 2 diabetes, or
angina pectoralis and had lower prevalences of hypertension
and type 2 diabetes than women with lower FSH levels. The
distributions of other factors did not differ significantly across
FSH quartiles.
Relationships between baseline characteristics and estradiol
levels are shown in Table 2. Women in the highest quartile of
estradiol had significantly higher BMI, waist:hip ratio, and
weight at age 20 years than women with lower levels. Mean tes-
tosterone, triglyceride, glucose, and insulin levels and mean sys-
tolic and diastolic blood pressure were higher in women with
higher estradiol levels, while FSH levels were lower. Women
with higher estradiol levels were more likely to report hyperten-
sion and use of antihypertensivemedication but not other cardio-
metabolic conditions.
In unadjusted analyses,mean IMTs decreased across quartiles
of FSH (Table 3). Mean IMTs of women in quartiles 1–4 of
FSH were 0.94mm, 0.91mm, 0.87mm, and 0.85mm, respec-
tively (P < 0.001). Mean IMT decreased with increasing FSH
levels in models adjusting for age, examination year, and
estradiol (model 1; P for trend < 0.001). Adjustment for
BMI and waist:hip ratio attenuated results only modestly
(model 2), and associations remained significant (P for trend =
0.001). Additional adjustment for behavioral and biochemical
factors (model 3) and comorbid conditions and medication use
(model 4) had a minimal impact on results, and a higher FSH
level remained significantly associated with lower IMT.
Regression coefficients for quartiles 2–4 of FSH versus quar-
tile 1 (model 4) were −0.038, −0.045, and −0.062, respec-
tively (P for trend = 0.01).
Estradiol levels were not linearly related to mean IMT
(Table 3). Unadjusted mean IMTs across quartiles 1–4 of estra-
diol were 0.88mm, 0.88mm, 0.87mm, and 0.93mm, respec-
tively (P = 0.03). In models that adjusted only for age, year, and
FSH, high estradiol levels were associated with higher IMT
(model 1; P for trend = 0.04). After further adjustment, results
were attenuated, and high estradiol levels were not associated
with higher IMT (model 4;P for trend = 0.33).
To facilitate comparison of our findings with those from pre-
vious studies of younger postmenopausal women, we stratified
the results by age group (ages 53–62 years vs. 64–73 years)
(Table 4). Mean FSH levels were marginally lower in older
women than in younger women (50.1 (standard deviation,
16.6) IU/L vs. 53.2 (standard deviation, 22.0) IU/L; P = 0.05).
Among older postmenopausal women, higher FSH levels were
related to lower mean IMT, with regression coefficients being
larger than those in the main analysis (P for trend = 0.006). In
contrast, among younger postmenopausal women (ages 53–62
years), FSH levels were not linearly associated with IMT (P for
trend = 0.73). The association between estradiol levels and
mean IMT also varied by age. Among younger postmenopausal
women, women with the highest estradiol levels had a greater
mean IMT than those with the lowest levels (P for trend =
0.03). In older postmenopausal women, associations with estra-
diol were not significant. Results stratified by median time since
menopause (15.3 years) were similar, with associations with
FSH being strongest in women who had been postmenopausal
longer (results not shown).
Because associations of FSH levels with IMT could poten-
tially be driven by adiposity, we then stratified our population
according to World Health Organization BMI category (<25.0
(normal-weight), 25.0–29.9 (overweight), or ≥30.0 (obese);
Table 5). We continued to adjust for BMI and waist:hip ratio
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Table 1. Characteristics of Women Aged 53–73 YearsWhoWere Not Using Hormone Therapy, by Quartile of Follicle-Stimulating Hormone
Concentration, Kuopio Ischemic Heart Disease Risk Factor Study, 1998–2001
Characteristic














Mean (SD) No. ofWomen % Mean (SD)
No. of
Women % Mean (SD)
No. of
Women % Mean (SD)
No. of
Women %
Age, years 64.5 (6.8) 65.1 (5.9) 64.4 (6.1) 62.9 (6.9) 0.02
Bodymass indexa 31.1 (5.7) 29.0 (5.4) 28.6 (4.7) 26.8 (4.4) <0.001
Waist:hip ratio 0.87 (0.07) 0.85 (0.06) 0.8 (0.1) 0.83 (0.06) <0.001
Estradiol, pmol/L 55.8 (77.6) 35.1 (19.8) 32.3 (12.3) 34.1 (19.5) <0.001
Testosterone, nmol/L 1.5 (2.9) 1.1 (0.5) 1.1 (0.5) 1.1 (0.5) 0.06
Sex hormone-binding
globulin, nmol/L
55.7 (25.7) 56.0 (27.9) 54.5 (26.6) 57.8 (27.9) 0.77
Systolic blood pressure,
mmHg
141 (20.4) 141 (17.3) 136 (16.3) 136 (16.4) 0.008
Diastolic blood pressure,
mmHg
80.9 (9.7) 80.5 (8.7) 79.5 (8.2) 80.3 (8.5) 0.60
Total cholesterol, mmol/L 5.6 (0.7) 5.8 (1.0) 5.8 (0.9) 5.9 (1.0) 0.009
Triglycerides, mmol/L 1.4 (0.7) 1.4 (0.8) 1.2 (0.5) 1.2 (0.6) 0.007
HDL cholesterol, mmol/L 1.3 (0.3) 1.3 (0.3) 1.4 (0.3) 1.4 (0.3) <0.001
LDL cholesterol, mmol/L 3.6 (0.7) 3.8 (1.0) 3.8 (0.9) 3.9 (1.0) 0.15
Glucose, mmol/L 5.3 (1.6) 5.2 (1.3) 5.0 (1.0) 4.9 (1.3) 0.03
Insulin, mU/L 12.0 (12.4) 9.5 (6.3) 8.3 (4.6) 7.3 (3.9) <0.001
C-reactive protein, mg/L 3.7 (7.7) 2.9 (4.7) 3.1 (4.9) 2.4 (2.8) 0.19
Physical activity (MET-hours/
day)
45.2 (5.9) 46.1 (7.1) 46.4 (6.1) 47.4 (7.5) 0.09
Alcohol intake, g/week 15.4 (32.2) 23.5 (53.2) 15.3 (29.5) 13.6 (26.1) 0.09
Age at menarche, years 13.7 (1.6) 14.0 (1.4) 14.1 (1.5) 13.9 (1.6) 0.18
Parity (no. of full-term
pregnancies)
2.5 (1.6) 2.4 (1.8) 2.5 (1.8) 2.0 (1.5) 0.02
Age at menopause, years 49.5 (4.5) 49.5 (4.4) 48.9 (5.3) 49.2 (4.3) 0.78
Years postmenopausal 15.0 (8.2) 15.6 (7.0) 15.4 (7.9) 13.6 (8.5) 0.14
Pack-years of smokingb 6.2 (11.6) 6.4 (13.9) 6.8 (11.1) 4.9 (11.4) 0.89
Smoking status
Never smoker 111 76 110 74 110 76 113 77
Current smoker 13 9 18 12 16 11 7 5 0.13
Past smoker 23 16 21 14 18 12 27 18 0.71
Ever use of oral
contraceptives
41 28 37 25 51 35 50 34 0.16
Past use of hormone therapy 41 28 47 32 50 34 53 36 0.45
Medical historyc
Heart disease 51 35 51 34 42 29 34 23 0.11
Diabetes 27 18 24 16 11 8 9 6 0.002
Hypertension 100 68 89 60 73 51 65 44 <0.001
Current medication usec
Heart disease 27 18 20 13 12 8 11 7 0.01
Diabetes 14 10 6 4 6 4 2 1 0.01
Hypertension 83 56 77 52 62 43 51 35 0.001
High cholesterol 5 3 11 7 7 5 4 3 0.23
Angina 25 17 18 12 11 8 7 5 0.004
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic equivalent of task; SD, standard deviation.
aWeight (kg)/height (m)2.
b Pack-years of cigarette smoking among ever smokers.
c Categories for medical history and current medication use were not mutually exclusive.
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Table 2. Characteristics of Women Aged 53–73 YearsWhoWere Not Using Hormone Therapy, by Quartile of Estradiol Concentration, Kuopio
Ischemic Heart DiseaseRisk Factor Study, 1998–2001
Characteristic














Mean (SD) No. ofWomen % Mean (SD)
No. of
Women % Mean (SD)
No. of
Women % Mean (SD)
No. of
Women %
Age, years 64.5 (6.4) 64.1 (6.7) 64.6 (6.6) 63.7 (6.3) 0.70
Bodymass indexa 26.2 (3.8) 27.6 (4.2) 29.1 (4.2) 33.1 (6.1) <0.001
Waist:hip ratio 0.82 (0.05) 0.84 (0.06) 0.86 (0.06) 0.87 (0.07) <0.001
Follicle-stimulating hormone,
IU/L
56.5 (20.1) 54.8 (17.7) 48.7 (15.8) 44.1 (19.6) <0.001
Testosterone, nmol/L 0.8 (0.4) 1.0 (0.5) 1.2 (0.5) 1.7 (3.0) <0.001
Sex hormone-binding globulin,
nmol/L
54.5 (25.6) 60.1 (30.4) 56.0 (26.8) 53.1 (24.1) 0.12
Systolic blood pressure,
mmHg
136 (18.0) 137 (16.1) 139 (19.6) 142 (17.2) 0.01
Diastolic blood pressure,
mmHg
78.8 (8.2) 80.1 (8.5) 80.0 (10.0) 82.7 (8.1) 0.001
Total cholesterol, mmol/L 5.6 (0.9) 5.8 (0.9) 5.9 (0.9) 5.7 (0.9) 0.09
Triglycerides, mmol/L 1.1 (0.5) 1.2 (0.6) 1.4 (0.7) 1.5 (0.8) <0.001
HDL cholesterol, mmol/L 1.4 (0.3) 1.4 (0.3) 1.3 (0.3) 1.3 (0.3) 0.04
LDL cholesterol, mmol/L 3.6 (0.9) 3.8 (0.9) 3.9 (0.9) 3.8 (0.9) 0.04
Glucose, mmol/L 4.8 (0.8) 4.9 (1.1) 5.2 (1.2) 5.5 (1.9) <0.001
Insulin, mU/L 6.9 (3.4) 8.7 (10.9) 9.7 (6.4) 12.1 (7.4) <0.001
C-reactive protein, mg/L 2.7 (3.9) 2.8 (4.7) 3.7 (7.9) 3.2 (4.3) 0.45
Physical activity, MET-hours/
day
47.6 (7.5) 45.7 (6.2) 45.4 (6.5) 46.0 (6.4) 0.02
Alcohol intake, g/week 14.7 (38.8) 13.7 (27.1) 23.1 (43.0) 17.7 (38.5) 0.15
Age at menarche, years 14.0 (1.5) 14.0 (1.5) 13.9 (1.3) 13.8 (1.7) 0.76
Parity (no. of full-term
pregnancies)
2.4 (1.7) 2.2 (1.4) 2.6 (1.8) 2.4 (1.6) 0.23
Age at menopause, years 49.0 (4.5) 49.5 (4.2) 49.5 (4.3) 49.4 (4.7) 0.76
Years postmenopausal 15.6 (7.9) 14.6 (7.7) 15.0 (8.0) 14.5 (8.2) 0.63
Pack-years of smokingb 7.1 (11.5) 4.6 (9.0) 8.6 (16.6) 3.4 (8.1) 0.25
Smoking status
Never smoker 120 76 123 77 89 70 112 79
Current smoker 18 11 13 8 15 12 8 6 0.38
Past smoker 20 13 24 15 23 18 22 15 0.23
Ever use of oral contraceptives 47 30 52 33 40 31 40 28 0.86
Past use of hormone therapy 50 32 65 41 37 29 39 27 0.07
Medical historyc
Heart disease 42 27 49 31 35 28 52 37 0.24
Diabetes 12 8 16 10 18 14 25 17 0.04
Hypertension 71 45 83 52 76 60 97 68 <0.001
Current medication usec
Heart disease 13 8 19 12 17 13 21 15 0.33
Diabetes 5 3 6 4 7 6 10 7 0.39
Hypertension 54 34 65 41 69 43 85 60 <0.001
High cholesterol 7 4 8 5 5 4 7 5 0.97
Angina 12 8 14 9 15 12 20 14 0.25
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic equivalent of task; SD, standard deviation.
aWeight (kg)/height (m)2.
b Pack-years of cigarette smoking among ever smokers.
c Categories for medical history and current medication use were not mutually exclusive.
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Table 3. Associations of Follicle-Stimulating Hormone and Estradiol LevelsWith Mean Carotid Intima-Media Thickness AmongWomen Aged 53–73 YearsWhoWere Not Using Hormone
Therapy, Kuopio Ischemic Heart Disease Risk Factor Study, 1998–2001




Model 1b Model 2c Model 3d Model 4e
β (SE)f P Value β (SE)f P Value β (SE)f P Value β (SE)f P Value
Follicle-stimulating
hormone, IU/L
Q1 32.1 0.94 (0.20) 0 (Referent) 0 (Referent) 0 (Referent) 0 (Referent)
Q2 45.1 0.91 (0.21) −0.044 (0.023) 0.06 −0.041 (0.023) 0.08 −0.038 (0.023) 0.09 −0.038 (0.023) 0.10
Q3 55.4 0.87 (0.16) −0.068 (0.023) 0.004 −0.065 (0.024) 0.006 −0.052 (0.023) 0.03 −0.045 (0.023) 0.05
Q4 72.8 0.85 (0.19) −0.085 (0.023) <0.001 −0.079 (0.024) 0.001 −0.066 (0.024) 0.007 −0.062 (0.024) 0.01
P for trend <0.001 <0.001 0.001 0.006 0.01
Estradiol, pmol/L
Q1 22.0 0.88 (0.18) 0 (Referent) 0 (Referent) 0 (Referent) 0 (Referent)
Q2 30.0 0.88 (0.20) 0.004 (0.022) 0.84 0.000 (0.022) 0.99 0.004 (0.022) 0.86 0.000 (0.022) 0.99
Q3 36.0 0.87 (0.17) −0.021 (0.024) 0.39 −0.027 (0.024) 0.26 −0.035 (0.025) 0.17 −0.036 (0.024) 0.16
Q4 49.0 0.93 (0.22) 0.049 (0.023) 0.04 0.037 (0.026) 0.16 0.031 (0.028) 0.27 0.028 (0.027) 0.31
P for trend 0.03 0.04 0.21 0.32 0.33
Abbreviations: IMT, intima-media thickness; MET, metabolic equivalent of task; Q, quartile; SD, standard deviation; SE, standard error.
a Unadjustedmean IMT (not transformed).
b Model 1 adjusted for age (years), date of examination (year), and estradiol (pmol/L) or follicle-stimulating hormone (IU/L) level (quartiles).
c Model 2 further adjusted for bodymass index (weight (kg)/height (m)2) and waist:hip ratio (continuous).
d Model 3 further adjusted for physical activity (MET-hours/day), past use of hormone therapy (yes, no), duration of use of hormone therapy (5 categories), smoking status (current, past, or
never smoker), pack-years of smoking (continuous), alcohol use (g/week), parity (number of full-term pregnancies), age at menopause (years; continuous), oophorectomy (yes, no), hysterec-
tomy (yes, no), systolic and diastolic blood pressure (mm Hg; continuous), and levels of testosterone (nmol/L), sex hormone-binding globulin (nmol/L), total cholesterol (mmol/L), low-density
lipoprotein cholesterol (mmol/L), high-density lipoprotein cholesterol (mmol/L), triglycerides (mmol/L), glucose (mmol/L), insulin (mU/L), and C-reactive protein (mg/L) (all natural log-trans-
formed; continuous).
e Model 4 further adjusted for history of hypertension, diabetes, symptomatic heart disease, and stroke (each dichotomous) and current use of medication for hypertension, heart disease,
high cholesterol, and diabetes (each dichotomous).
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(both continuous) to minimize residual confounding within
strata. We did not observe evidence that the association of
FSH or estradiol with mean IMT varied significantly by
BMI (all P’s for interaction > 0.05). Although sample sizes
for some comparisons were relatively small, we observed
lower IMTs among women with higher FSH levels in all
strata.
Results from analyses limited to women without prevalent
CVD (n = 395) were similar to those from the main analysis
(complete results not shown); regression coefficients for quar-
tiles 2–4 of FSH versus quartile 1 (model 4) were −0.057,
−0.055, and −0.098, respectively (P for trend = 0.002). Re-
sults from analyses excluding women who were currently
using medication for CVD, hypertension, high cholesterol, or
diabetes (n = 301) were slightly attenuated (complete results
not shown); regression coefficients for quartiles 2–4 of FSH
versus quartile 1 (model 3) were−0.034,−0.007, and−0.056,
respectively (P for trend = 0.06). Furthermore, we did not
observe evidence of effect modification by prevalent hyper-
tension (results not shown).
FSH levels were significantly associated with maximum IMT
(results not shown); for example, regression coefficients for
quartiles 2–4 versus quartile 1 (model 4) were −0.030, −0.038,
and −0.050, respectively (P for trend = 0.009). Estradiol was
not associated withmaximum IMT (results not shown).
DISCUSSION
We observed a significant inverse association between FSH
levels and measures of subclinical atherosclerosis among post-
menopausal women. Findings were most pronounced among
women aged 64–73 years. To our knowledge, the association
between FSH and IMT in older postmenopausal women who
have completed the menopausal transition has not been previ-
ously evaluated. Importantly, our findings were not explained
by confounding by adiposity, estradiol, or sex hormone-binding
globulin levels or prevalent cardiometabolic disorders.
The magnitude of observed associations between FSH and
IMT was difficult to interpret given our transformation of IMT
data to improve normality. In unadjusted analyses of untrans-
formed IMT data, mean IMT differed by 0.09mm between the
highest and lowest quartiles of FSH, a difference of 9.6%. For
comparison, unadjusted mean IMT was 3.1% higher in obese
Table 4. Associations of Follicle-Stimulating Hormone and Estradiol LevelsWith Mean Carotid Intima-Media Thickness AmongWomen Aged










(SD), mmb β (SE)
c P Value No. ofWomen
Mean IMT




Q1 32.1 61 0.87 (0.17) 0 (Referent) 86 0.99 (0.20) 0 (Referent)
Q2 45.1 49 0.84 (0.25) −0.036 (0.044) 0.42 100 0.94 (0.19) −0.028 (0.029) 0.33
Q3 55.4 59 0.81 (0.12) −0.033 (0.042) 0.44 85 0.91 (0.17) −0.047 (0.030) 0.12
Q4 72.8 74 0.81 (0.19) −0.024 (0.041) 0.56 73 0.89 (0.17) −0.089 (0.032) 0.007
P for trend 0.28 0.73 0.003 0.006
Estradiol, pmol/Le
Q1 22.0 63 0.78 (0.11) 0 (Referent) 95 0.94 (0.18) 0 (Referent)
Q2 30.0 67 0.83 (0.20) 0.043 (0.039) 0.27 93 0.92 (0.18) −0.019 (0.029) 0.50
Q3 36.0 49 0.80 (0.12) 0.023 (0.044) 0.60 78 0.91 (0.18) −0.061 (0.032) 0.06
Q4 49.0 64 0.90 (0.24) 0.109 (0.048) 0.02 78 0.96 (0.20) −0.004 (0.036) 0.90
P for trend 0.002 0.03 0.37 0.83
Abbreviations: IMT, intima-media thickness; MET, metabolic equivalent of task; Q, quartile; SD, standard deviation; SE, standard error.
a Women from 4 specific age groups were selected for the study: 53–56 years, 59–62 years, 64–68 years, and 71–73 years.
b Unadjustedmean IMT (not transformed).
c Mean IMT values were transformed (negative reciprocal transformation) to improve normality. Results were adjusted for age (years; continu-
ous), date of examination (year), body mass index (weight (kg)/height (m)2; continuous), waist:hip ratio (continuous), estradiol (pmol/L) or follicle-
stimulating hormone (IU/L) level (quartiles), physical activity (MET-hours/day), past use of hormone therapy (yes, no), duration of use of hormone
therapy (5 categories), smoking status (current, past, or never smoker), pack-years of smoking (continuous), alcohol use (g/week), parity (number
of full-term pregnancies), age at menopause (years; continuous), oophorectomy (yes, no), hysterectomy (yes, no), systolic and diastolic blood pres-
sure (mmHg; continuous), levels of testosterone (nmol/L), sex hormone-binding globulin (nmol/L), total cholesterol (mmol/L), low-density lipoprotein
cholesterol (mmol/L), high-density lipoprotein cholesterol (mmol/L), triglycerides (mmol/L), glucose (mmol/L), insulin (mU/L), and C-reactive protein
(mg/L) (all natural log-transformed; continuous), history of hypertension, diabetes, symptomatic heart disease, and stroke (each dichotomous), and
current use of medication for hypertension, heart disease, high cholesterol, and diabetes (each dichotomous).
d Interaction with age:P = 0.13.
e Interaction with age: P= 0.02.
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Table 5. Associations of Follicle-Stimulating Hormone and Estradiol LevelsWith Mean Carotid Intima-Media Thickness AmongWomen Aged 53–73 YearsWhoWere Not Using Hormone










(SD), mmb β (SE)
c P Value No. ofWomen
Mean IMT
(SD), mmb β (SE)
c P Value No. ofWomen
Mean IMT




Q1 32.1 22 0.94 (0.20) 0 (Referent) 43 0.93 (0.23) 0 (Referent) 81 0.94 (0.18) 0 (Referent)
Q2 45.1 34 0.89 (0.19) −0.144 (0.064) 0.03 60 0.93 (0.24) −0.019 (0.044) 0.67 55 0.90 (0.19) −0.038 (0.032) 0.24
Q3 55.4 33 0.86 (0.16) −0.108 (0.065) 0.10 61 0.88 (0.15) 0.003 (0.044) 0.94 51 0.86 (0.16) −0.081 (0.034) 0.02
Q4 72.8 57 0.84 (0.18) −0.107 (0.060) 0.08 61 0.84 (0.16) −0.085 (0.045) 0.06 29 0.90 (0.24) −0.026 (0.039) 0.51
P for trend 0.41 0.10 0.24
Estradiol, pmol/Le
Q1 22.0 62 0.88 (0.18) 0 (Referent) 75 0.87 (0.17) 0 (Referent) 21 0.90 (0.20) 0 (Referent)
Q2 30.0 43 0.85 (0.18) −0.074 (0.051) 0.16 74 0.91 (0.23) 0.037 (0.036) 0.30 43 0.87 (0.15) 0.011 (0.050) 0.83
Q3 36.0 26 0.85 (0.21) −0.111 (0.061) 0.07 49 0.88 (0.17) 0.038 (0.043) 0.39 52 0.87 (0.14) −0.045 (0.050) 0.37
Q4 49.0 15 0.90 (0.16) −0.040 (0.073) 0.58 28 0.92 (0.25) 0.024 (0.052) 0.65 99 0.94 (0.22) 0.051 (0.049) 0.30
P for trend 0.29 0.57 0.09
Abbreviations: IMT, intima-media thickness; FSH, follicle-stimulating hormone; MET, metabolic equivalent of task; Q, quartile; SD, standard deviation; SE, standard error.
aWeight (kg)/height (m)2.
b Unadjustedmean IMT (not transformed).
c Mean IMT values were transformed (negative reciprocal transformation) to improve normality. Results were adjusted for age (years; continuous), date of examination (year), body mass
index (weight (kg)/height (m)2; continuous), waist:hip ratio (continuous), estradiol (pmol/L) or follicle-stimulating hormone (IU/L) level (quartiles), physical activity (MET-hours/day), past use of
hormone therapy (yes, no), duration of use of hormone therapy (5 categories), smoking status (current, past, or never smoker), pack-years of smoking (continuous), alcohol use (g/week), parity
(number of full-term pregnancies), age at menopause (years; continuous), oophorectomy (yes, no), hysterectomy (yes, no), systolic and diastolic blood pressure (mmHg; continuous), levels of
testosterone (nmol/L), sex hormone-binding globulin (nmol/L), total cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L), high-density lipoprotein cholesterol (mmol/L), triglycer-
ides (mmol/L), glucose (mmol/L), insulin (mU/L), and C-reactive protein (mg/L) (all natural log-transformed; continuous), history of hypertension, diabetes, symptomatic heart disease, and
stroke (each dichotomous), and current use of medication for hypertension, heart disease, high cholesterol, and diabetes (each dichotomous).
d Interaction with bodymass index: P= 0.67.
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women than in normal-weight women (P = 0.20) and 9.8%
higher in women with hypertension versus women without it
(P< 0.001), suggesting a level of difference comparable inmag-
nitude to that of established risk factors for atherosclerosis.
To our knowledge, an inverse association between FSH and
IMT has not been observed before. The few previous studies of
FSH and atherosclerosis have assessed this relationship during
the menopausal transition, when participants were probably still
experiencing significant fluctuations in FSH and estradiol levels
(1–5). In 2 of these studies, investigators reported only unad-
justed correlation coefficients and thus did not account for
potential confounding by age, adiposity, estradiol, or other fac-
tors (4, 5).
The other studies of FSH and IMTwere conducted within the
Study ofWomen’s Health Across the Nation (1–3). In a cross-
sectional analysis carried out when participants were aged
45–58 years (mean age= approximately 50 years), FSH level
was not associated with IMT (3). In subsequent work, partici-
pants were characterized by trajectory of change in FSH and
estradiol levels across the menopausal transition (16). El
Khoudary et al. (1) then evaluated how the trajectory predicted
mean IMT approximately 8 years after thefinalmenstrual period
(mean age = 59 years). After adjustment, IMT was significantly
greater in women with the most common “medium” trajectory
of FSH increase (n = 431) than in those with the lowest trajec-
tory (n = 53). Interestingly, IMT was not significantly higher in
women with the highest trajectory (n = 372), suggesting a non-
linear relationship. Estradiol pattern was not significantly associ-
ated with mean IMT. It is notable that FSH levels continued to
change for 10 years after the final menstrual period, underscor-
ing the extended duration of the hormonal changes of meno-
pause and the inherent difficulty of capturing associations of
hormones with long-term cardiovascular health during this
period. FSH levels during this dynamic period may be differ-
ently associated with atherosclerosis than themore stable levels
attained after the menopausal transition is complete.
Few studies have characterized FSH in older postmenopausal
women. Shaw et al. (17) reported that FSH levels were signifi-
cantly lower in women aged 70–77 years (average of 27 years
after menopause) than in women aged 48–57 years (average of
4 years after menopause), though estradiol levels did not vary.
FSH response to gonadotropin-releasing hormone was also lower
in the older postmenopausal women versus the younger ones.
This is consistent with our study.
The structure of FSH may be physiologically different in
postmenopausal women and premenopausal women (18). FSH
exists in multiple isoforms, with sialic acid and sulfonated
N-acetylgalactosamine residues varying by isoform and influ-
encing the half-life of the molecule. Wide et al. (18) report that
FSH ismore negatively charged after menopause due to a higher
number of sialic acid molecules on postmenopausal isoforms,
and this greater acidity is consistent with a longer half-life
in vivo. Additionally, the distribution of isoforms changes with
age and additionally varies across individuals, contributing fur-
ther to individual differences.
The inverse association we observed between FSH level
and IMT could plausibly be explained by relationships of
FSH with estradiol and adiposity. It is well established that
obese women have worse CVD risk profiles and higher IMT
measurements than lean women (19, 20). After menopause,
obesity is associated with higher estradiol levels, due to the
aromatization of androgens to estrogens in adipose tissue.
Estradiol produced extragonadally could then suppress FSH
secretion through negative feedback, leading to lower FSH
levels in women with greater adiposity. Strong inverse corre-
lations of FSH with adiposity measures have in fact been
observed in this study and in other observational studies (1,
4, 6, 21). In a cohort study conducted within the Diabetes
Prevention Project, Kim et al. (22) observed increases in
FSH accompanying weight loss among overweight glucose-
intolerant postmenopausal women. In our study, the inverse
association between FSH and IMT that we observed was not
explained by adiposity and estradiol, as associations per-
sisted after adjustment for and stratification by these factors.
Activins and follistatin may also play a role in these relation-
ships. Activins A, B, and AB, members of the transforming
growth factor β superfamily, stimulate FSH secretion by the
pituitary gland. FSH secretion via activins is inhibited by bind-
ing of the protein hormone follistatin. Ample evidence indicates
that the activins and follistatin together play a role in regulating
adipogenesis, inflammation, insulin resistance, and atherosclero-
sis (23, 24). Interaction between the activins and follistatin has
also been evaluated in the context of polycystic ovary syndrome,
a reproductive condition associated with reduced FSH levels,
increased adiposity, insulin resistance, and inflammation, in
addition to hyperandrogenism and anovulation (25). Teede et al.
(26) observed higher follistatin levels in polycystic ovary syn-
drome patients than in controls, as well as significant correla-
tions of follistatin and/or activin A with lipids, inflammatory
markers, and insulin. The authors proposed that these hormones
may be an important physiological link between the reproduc-
tive and metabolic features of polycystic ovary syndrome. Fol-
listatin levels decline and activin bioavailability increases across
the menopausal transition, likely contributing to the increase in
FSH levels after menopause (27). Our findings for FSH may
potentially reflect downstream hormonal effects of activins
or follistatin or their interactionwith insulin resistance on athero-
sclerotic processes in late menopause, manifesting as reduced
sensitivity of the hypothalamic-pituitary-gonadal axis. This is an
important area for further study.
Our study had several important limitations. Because our
study was cross-sectional, we were unable to assess the tempo-
rality of the relationship between FSH and IMT. Our assessment
of subclinical atherosclerosis was limited to measurement of
CCA IMT, which is well established as a predictor of future car-
diovascular events (28, 29) but may not characterize atheroscle-
rosis as comprehensively as measures of carotid plaques, carotid
artery diameter, and coronary artery calcification (30, 31). Pro-
spective studies assessing how FSH levels are associated with
these measures, atherosclerosis progression, and incident CVD
will be essential for determining both the reproducibility of our
findings and their clinical importance. Because the KIHD study
population is very homogenous with respect to race and ethnic-
ity, additional evaluation of these relationships in diverse popu-
lations is needed. Additionally, studies assessing the role of
additional sex steroid and pituitary hormones such as estrone,
androstenedione, and follistatin will be important for better
understanding the physiology of FSH and atherosclerosis in
older women. Strengths of our study include the availability of
extensive data on biochemical and clinical CVD risk factors,
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allowing us to comprehensively evaluate potential confounding
and effect modification.
To our knowledge, this was the first study of FSH and mark-
ers of subclinical atherosclerosis in older postmenopausal
women. We observed evidence of significantly lower IMT in
women with the highest FSH levels, which was not explained
by estradiol, adiposity, or other factors. The potential clinical im-
plications of these findings are uncertain at this time. Additional
studies of FSH and cardiovascular health outcomes in older
postmenopausal women are needed to determine whether these
findings are robust and, if so, to further explore potential under-
lying physiological explanations.
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